Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.